Analysis of different innovative formulations of curcumin for improved relative oral bioavailability

Analysis of different formulations of curcumin for improved relative oral bioavailability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17535884

Enrollment

Registered

2015-12-29

Start date

2013-05-02

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional supplement Nutritional, Metabolic, Endocrine

Interventions

Four curcumin supplement formulations were used (BCM-95® [Dolcas], Meriva® [Indena], C3 ComplexTM [Sabinsa Corporation] and CAVAMAX® W8 Curcumin/CAVACURMIN® [Wacker Chemie AG]. All volunteers were su

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy individuals 2. Age: 20-35 years 3. Males and females 4. Participants agreed to sign an informed consent form 5. Participants must be able to perform required testing

Exclusion criteria

Exclusion criteria: 1. Consuming any curcumin-containing supplements or foods for two weeks prior to testing 2. History of any of the following: hyperacidity, gastric/duodenal ulcers, gastrointestinal problems, gallbladder issues 3. Use of any blood thinners/anti-thrombotic agents or NSAIDS 4. Prior use of blood sugar-lowering agents, H2 blockers, or proton pump inhibitors 5. Known allergies to soy 6. Diabetics 7. Pregnancy

Design outcomes

Primary

Measure	Time frame
1. Peak plasma concentrations Tmax (h) 2. Area under the plasma concentration time-curve (AUC 0-12), Cmax (ng/mL) and T1/2 (h) Plasma levels of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-12h), Cmax, t1/2 and relative absorption will be calculated.	—

Measure

Time frame

1. Peak plasma concentrations Tmax (h) 2. Area under the plasma concentration time-curve (AUC 0-12), Cmax (ng/mL) and T1/2 (h) Plasma levels of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-12h), Cmax, t1/2 and relative absorption will be calculated.

—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026